Pipeline marketing for biopharma to build brand awareness before product launch

Key takeaways

• Pipeline marketing builds disease awareness, scientific credibility and stakeholder relationships during clinical development, without promoting an unapproved product.
• Competition for attention is real: FDA’s drug center approved 46 novel drugs in 2025, 58 including biologics reviewed by CBER, with about half for rare diseases.
• The core pre-launch tools are unbranded disease awareness, genuine KOL collaboration, publications, digital education and patient advocacy partnerships.
• Payer preparation starts early through health economics research, value dossiers and pre-approval information exchange permitted under FDA guidance.
• Medical affairs, commercial and compliance teams need one shared plan, and pre-launch success is measured by inputs such as KOL engagement, physician perception and payer readiness.

Waiting until FDA approval to start building your brand puts a launch at a disadvantage. Many successful biopharma launches come from companies that spent the 18 to 24 months before approval shaping how physicians, patients and payers understand the disease and the science. This guide explains how pipeline marketing works and how to build awareness before launch while staying within FDA rules.

What is pipeline marketing in biopharma?

Pipeline marketing is marketing that begins during clinical development, usually around Phase 2 or Phase 3, to build awareness of a disease, the unmet need and the company’s scientific expertise. It does not promote the investigational product, which FDA regulations prohibit before approval.

FDA rules bar companies from representing an investigational drug as safe or effective for the uses under study. Pre-approval communication therefore focuses on unbranded disease education, scientific exchange led by medical affairs and corporate or institutional messages. Done well, it makes your company a trusted voice in the therapy area before the product can be named.

At Emulent, we see many biopharma companies treat pre-launch marketing as a checklist item. Those that break through invest years in earning the trust of physicians and patient communities first.

Why does starting early give you a competitive edge?

Starting early gives you an edge because physicians, payers and advocacy groups form opinions over years of exposure, and the companies already part of the scientific conversation are best placed when a product reaches the market.

The field is crowded. FDA’s Center for Drug Evaluation and Research approved 46 novel drugs in 2025, and 58 novel approvals counting those from the biologics center. Each new therapy competes for limited physician attention, formulary decisions and patient awareness.

Four advantages of early pipeline marketing:

• Physician familiarity. Clinicians who know your company through medical education, congress presentations and publications approach a new therapy with less hesitation.
• Patient identification. Disease awareness helps more people get diagnosed and into care, especially in underdiagnosed conditions.
• Payer readiness. Early, permitted scientific exchange gives payers time to review evidence before coverage decisions.
• A faster ramp. When groundwork is in place, adoption in the first months after launch tends to move faster.

What are the core components of a pre-launch biopharma marketing strategy?

The core components are disease awareness campaigns, KOL development and scientific storytelling, a digital strategy for physicians and patients and a publication plan. Each reaches a different decision-maker and deserves a place in the budget.

Disease awareness campaigns

Disease awareness campaigns are the most widely used pre-approval tool. They inform physicians and patients about a condition’s prevalence, underdiagnosis, treatment gaps and the case for new approaches, without naming or implying a specific product. Keep them unbranded, and review them with regulatory counsel so they can’t be read as promoting the investigational drug.

Run them across medical journals, congresses, patient organizations, digital media and professional associations. Consistency over months builds more awareness than a short burst.

KOL development and scientific storytelling

Leading clinical experts, often called KOLs, shape how new therapies are adopted. Researchers who publish on your mechanism and present at major meetings carry credibility no campaign can buy.

Pre-launch KOL engagement should rest on genuine scientific collaboration: supporting investigator-initiated research, running advisory boards for feedback and contributing to education. Payments to physicians must be reported under the federal Open Payments program, and arrangements should follow the Anti-Kickback Statute and the PhRMA Code.

Scientific content often misses because it’s accurate but disconnected from the clinical problems physicians face daily. Ground stories in patient cases and practice realities.

Digital channel strategy for physician and patient reach

Physicians increasingly turn to digital sources for clinical data, medical news and professional networking, so a pre-launch digital plan puts disease education where they already look.

Five digital channels for pre-launch awareness:

• Medical education platforms. Sites such as Medscape reach licensed clinicians with disease education across specialties.
• Search content. Condition-specific pages that rank for clinical queries make your company a resource early. Our content strategy services and healthcare marketing team build these programs.
• LinkedIn. Medical affairs professionals, researchers and KOLs are active there, making it useful for corporate and scientific visibility.
• Congresses and webinars. Virtual sessions and accredited education reach clinicians with disease-state perspectives, within rules separating education from promotion.
• Patient communities. Disease-specific communities and organizations such as NORD connect you with advocacy groups that can become long-term partners.

Publication strategy

Peer-reviewed publications are the strongest credibility builder in biopharma. Publishing Phase 2 and Phase 3 data puts results into the scientific record before launch, so physicians have seen the evidence by the time the product is available.

Plan publications before trials end, choose target journals and coordinate manuscript development with medical affairs. Abstracts, posters and presentations at specialty meetings extend reach. Follow good publication practice guidelines on authorship and disclosure.

How do you build a patient advocacy strategy before launch?

Build a patient advocacy strategy by investing in real relationships long before launch: attending community events, supporting education through independent grants, contributing to registries and listening to what patients and caregivers need. Advocacy groups carry influence with patients, payers and regulators that paid media can’t match.

What you learn from those relationships should shape trial design, support services and messaging.

Four parts of a pre-launch advocacy program:

• Registry support. Partnering on patient registries generates real-world data and goodwill.
• Independent educational grants. Grants to advocacy organizations for disease education, without control over content, show the company backs the community.
• Patient advisory boards. Patients and caregivers give direct insight into unmet needs and everyday barriers.
• Co-developed materials. Educational resources created with advocacy groups reach people a company couldn’t reach alone.

Companies that treat advocacy as a launch-day publicity move tend to struggle. The most credible relationships in rare and specialty disease were built years earlier.

How should market access and payer communications work during the pipeline phase?

Market access work should begin well before approval, because payers need time to review evidence, run internal processes and plan budgets. Treating payer marketing as a post-approval task leaves products waiting for coverage.

FDA’s guidance on drug and device manufacturer communications with payors allows companies to share certain unbiased information about investigational products, such as product information, anticipated timelines and clinical study results, with payers and formulary committees before approval, provided it’s clearly labeled and not promotional.

Four pre-launch access activities that pay off:

• Health economics and outcomes research. Cost-effectiveness models and real-world evidence give payers the data they need.
• Pre-approval information exchange. Non-promotional meetings with health plan medical and pharmacy directors, consistent with FDA’s payor guidance.
• A value dossier. A complete dossier ready at approval lets access teams engage payers immediately.
• Patient support planning. Designing assistance and affordability programs early shows payers and advocates that access barriers are being addressed, within OIG guidance.

How do you align medical affairs, commercial and marketing before launch?

Align the teams with one shared plan and clear roles: medical affairs leads scientific exchange, publications and KOL engagement; commercial leads positioning, market research and launch readiness; and regulatory and legal review everything that reaches external audiences. Misalignment is one of the most common pre-launch problems.

Medical affairs decides what can be shared before approval, while commercial shapes how the brand will be positioned. Regular joint planning keeps messages consistent and compliant, so disease education, scientific narrative and eventual brand positioning tell the same story.

How do you measure pre-launch brand awareness?

Measure pre-launch awareness with input metrics suited to the stage: KOL engagement, disease content performance, physician perception, advocacy relationships, scientific reach and payer engagement. Before a product can be named, you’re measuring the foundation for commercial success.

Six measures that show you’re building the right foundation:

How do you build the awareness your launch needs?

Build the awareness your launch needs by starting during clinical development with disease education, scientific credibility, advocacy relationships and payer preparation, all coordinated across medical, commercial and compliance teams. The gap between a strong launch and a slow one often comes from what happened before approval.

A counterpoint: pre-launch investment carries risk, because trials can fail or approvals can slip. Disease awareness and scientific relationships hold value for a company’s broader pipeline even if one asset doesn’t succeed, which is another reason to keep them unbranded.

At Emulent, we help biopharma companies plan and run compliant pre-launch marketing programs. Contact Emulent if you have a product approaching Phase 3 or regulatory submission.